A newly reported US patent protects Annovis Bio’s more stable crystal form of experimental Alzheimer’s drug buntanetap through 2044. The milestone comes as a randomized phase 3 trial tests the oral therapy in adults with early disease.
Annovis Bio has reportedly secured a US patent covering Form B, the crystal form of its experimental Alzheimer’s drug buntanetap now being used in late-stage development, with protection said to run through 2044. A report on the patent grant describes the claims as applying to the version being tested in a pivotal phase 3 trial.
The development potentially gives Annovis a longer commercial runway if buntanetap proves effective and gains regulatory approval. It also illustrates an important distinction in drug development: two products can contain the same active ingredient while differing in their crystalline structure, stability and intellectual-property status.
A patent is not evidence that a treatment works, and its reported term does not alter the clinical threshold buntanetap must meet. Its relevance is that Annovis has aligned its patent position with the formulation selected for a large, randomized trial in early Alzheimer’s disease.
A new solid form of an existing drug candidate
Drug molecules can arrange themselves into more than one crystalline structure, known as polymorphs. They may also incorporate water into that structure. These differences do not necessarily change the identity of the active molecule, but they can affect characteristics such as stability, storage, dissolution and the consistency of large-scale manufacturing.
A 2025 peer-reviewed development report described buntanetap Form B as a novel dihydrate crystal form. The earlier Form A was a semi-crystalline anhydrate used in previous preclinical and clinical work. According to the paper, Form B had improved solid-state stability and pharmacokinetic profiles comparable with Form A across the species studied.
That is useful development evidence rather than proof of therapeutic benefit. Greater solid-state stability can make a candidate easier to manufacture, handle and store reliably. Comparable pharmacokinetics suggest that changing the crystal form did not substantially alter how the active compound behaved in the reported comparisons. Neither finding establishes that Form B improves cognition or changes the course of Alzheimer’s disease in people.
The distinction helps explain why the patent matters. The protected feature is the drug’s physical form, not a newly discovered active ingredient. As reported, Annovis is seeking to protect the formulation it intends to carry through pivotal testing and, if the clinical and regulatory results permit, into the market.
Phase 3 is testing the clinical proposition
The federal trial registry lists DUET-AD as a randomized, double-blind, placebo-controlled phase 3 study in adults aged 55 to 85 with early Alzheimer’s disease. Participants receive either oral buntanetap at 30 mg once daily or placebo. The registry record lists an 18-month treatment period and classifies the trial as active but not recruiting.
A peer-reviewed description of the program said it began in March 2025 and planned to randomize 760 participants at as many as 100 US sites. The trial was structured around a six-month assessment of symptomatic effects, followed by an 18-month stage intended to assess potential disease-modifying effects.
That separation is clinically meaningful. A short-term change in cognitive or functional performance may reflect symptomatic benefit without showing that a therapy has altered the underlying disease trajectory. A longer trial can examine whether differences persist or develop over time, although interpretation ultimately depends on the prespecified endpoints and the strength and consistency of the results.
The phase 3 status signals that buntanetap has moved beyond initial safety and dose-finding work, but it does not imply that efficacy has already been demonstrated. The randomized placebo comparison is the test that must determine whether the formulation selected for development produces a clinically meaningful benefit in the target population.
Earlier results produced a signal, not a broad win
The evidentiary backdrop is a previous double-blind, placebo-controlled phase 2/3 dose-ranging study involving 353 people with mild-to-moderate Alzheimer’s disease. Participants received placebo or 7.5 mg, 15 mg or 30 mg of buntanetap once daily.
In the overall study population, the trial did not establish a statistically significant cognitive benefit, and there was no significant difference on the Clinical Global Impression of Change endpoint. That global measure captures a clinician’s assessment of whether a participant has improved, remained stable or worsened.
Investigators did, however, report a statistically significant improvement on the ADAS-Cog11 cognitive scale among participants in a mild Alzheimer’s subgroup. A subsequent peer-reviewed account made clear that this was an exploratory rather than prespecified subgroup analysis.
Exploratory subgroup findings can identify a plausible population for further study, especially when a treatment may work differently at different stages of disease. They are not equivalent to a positive result in the full trial because dividing participants after data are available raises the probability of chance findings. The current focus on early Alzheimer’s disease makes the earlier signal directly relevant, while also placing the burden on phase 3 to reproduce it prospectively in a larger randomized population.
The patent and clinical clocks now run together
For Annovis, protection reportedly extending to 2044 could become commercially important if buntanetap succeeds. A longer patent horizon may preserve the value of the specific formulation during development and after a possible launch. Its practical worth, however, depends on the drug completing clinical testing, obtaining approval and being used in the protected form.
The formulation work and the pivotal trial therefore answer different questions. The peer-reviewed solid-state research supports Form B as a more stable development candidate with broadly comparable pharmacokinetic behavior to the earlier form. DUET-AD is testing whether 30 mg daily produces meaningful clinical effects in adults with early Alzheimer’s disease.
That makes the patent a strategic milestone rather than a clinical verdict. The decisive evidence for patients and practitioners will come from the randomized phase 3 results—particularly whether any benefit is statistically robust, clinically meaningful and consistent across the trial’s cognitive and functional assessments.